VIDEO: Giredestrant improves breast cancer survival, regardless of menopause status

CHICAGO — In this video, Shimoli Barot, MD, discusses results from the phase 3 lidERA BC clinical trial, which assessed efficacy and safety of adjuvant giredestrant in premenopausal vs. postmenopausal women with breast cancer. Findings from the study, which compared giredestrant (Genentech, Roche) with standard-of-care endocrine therapy in ER-positive, HER2-negative early breast cancer, were